Vriligy 60 mg, containing the active ingredient dapoxetine, belongs to a class of medications known as selective serotonin reuptake inhibitors (SSRIs). Originally developed to treat PE, Vriligy 60 mg has garnered attention for its potential role in managing ED. By modulating serotonin levels in the brain, Vriligy 60 mg can help improve ejaculatory control and enhance satisfaction. Clinical studies have demonstrated the efficacy of Vriligy 60 mg in diabetic patients with ED. Its ability to enhance erectile function and delay makes it a valuable addition to the treatment armamentarium for diabetic men struggling with dysfunction. However, dosage adjustments and careful monitoring may be necessary due to potential drug interactions and individual patient factors.